AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
13min chapter
Lilly’s Zepbound Cuts Risk of Diabetes
Bloomberg Intelligence
Eli Lilly's Obesity Drugs and Diabetes Management
This chapter examines Eli Lilly's obesity-related drugs and their possible effects on diabetes management, discussing the potential health benefits of weight loss. It highlights the disparity between clinical trial results and real-world drug effectiveness, addressing patient adherence challenges and the implications for pharmaceutical stock performance. Additionally, it provides insights into the evolving landscape of diabetes treatment, the development of oral medications, and the impact of upcoming competitive data.
00:00
Transcript
Episode notes
Get the Snipd
podcast app
Unlock the knowledge in podcasts with the podcast player of the future.
AI-powered
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode
Save any
moment
Hear something you like? Tap your headphones to save it with AI-generated key takeaways
Share
& Export
Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more
AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode